Core Insights - Liquidia Corporation is a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, utilizing its proprietary PRINT Technology for innovative treatments, particularly in pulmonary hypertension [1] Stock Performance - On November 3, 2025, Jefferies upgraded Liquidia's stock to a "Buy" rating at a price of $25.22, with an increased price target from $43 to $45, resulting in a 3.53% increase in stock price, or $0.86 [2] - The stock price fluctuated between $22.25 and $27.23 on the announcement day, with a yearly high of $29.94 and a low of $9.71, indicating significant volatility [4] - Liquidia's market capitalization is approximately $2.17 billion, with a trading volume of 7.25 million shares, reflecting strong investor interest [4] Earnings Call Insights - The Q3 2025 earnings call featured key executives, including CEO Roger Jeffs and CFO Michael Kaseta, and involved participation from major research divisions like Jefferies LLC and Wells Fargo Securities, providing insights into financial performance and strategic plans [3] - The strategic direction discussed in the earnings call emphasizes leveraging proprietary technology to enhance product offerings and market presence in the biopharmaceutical sector [5]

Core Viewpoint - Liquidia Corporation is set to report its third quarter 2025 financial results on November 3, 2025, and will host a webcast to discuss these results and provide a corporate update [1]. Group 1: Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3]. - The company is currently developing and commercializing products for pulmonary hypertension using its proprietary PRINT Technology [3]. - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3]. - The company is also working on L606, an investigational sustained-release formulation of treprostinil, which is administered twice daily with a next-generation nebulizer [3]. - Additionally, Liquidia markets a generic version of Treprostinil Injection for PAH treatment [3]. Group 2: Webcast Information - The upcoming webcast will be available on Liquidia's website and will be archived for one year [2].

Core Insights - Liquidia Corporation will present two oral presentations at the CHEST 2025 annual meeting focusing on new data from the ASCENT trial related to LIQ861 DPI treprostinil in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1][2] Group 1: Presentation Details - The first presentation titled "Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from ASCENT" will be held on October 21, 2025, at 10:20 a.m. CT, presented by Dr. Dan Lachant [3] - The second presentation titled "Safety and Exploratory Efficacy Data of LIQ861 DPI Treprostinil in PH-ILD: ASCENT to Week 16" will also take place on October 21, 2025, at 1:52 p.m. CT, presented by Dr. Nicholas Kolaitis [3] Group 2: ASCENT Study Overview - The ASCENT study is an open-label, prospective, multicenter trial evaluating the safety and tolerability of LIQ861 in subjects with WHO Group 1 and 3 pulmonary hypertension, specifically focusing on a cohort of 54 subjects with PH-ILD [4] - The primary objective of the study is to assess the safety and tolerability of LIQ861, while exploratory objectives include evaluating its effects on exercise capacity, functional class, biomarkers, and imaging assessments [4] Group 3: Product Information - YUTREPIA™ is an inhaled dry-powder formulation of treprostinil designed for the treatment of pulmonary arterial hypertension (PAH) and PH-ILD, aimed at improving exercise ability [5] - The product utilizes Liquidia's PRINT technology, which allows for the creation of drug particles that are precise and uniform, enhancing deposition in the lungs [5] Group 4: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, with a current emphasis on pulmonary hypertension and applications of its proprietary PRINT technology [6] - The company has developed YUTREPIA™ as its first approved product and is also working on L606, an investigational sustained-release formulation of treprostinil [6]

Core Viewpoint - Liquidia Corporation is set to report its second quarter 2025 financial results on August 12, 2025, and will host a webcast to discuss these results and provide a corporate update [1]. Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3]. - The company is engaged in the development and commercialization of products targeting pulmonary hypertension, utilizing its proprietary PRINT Technology [3]. - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is designed for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3]. - The company is also working on L606, an investigational sustained-release formulation of treprostinil, which is administered twice daily using a next-generation nebulizer [3]. - Additionally, Liquidia markets a generic version of Treprostinil Injection for PAH treatment [3].

Core Insights - Liquidia Corporation will provide a business update during a fireside chat at the 2025 Jefferies Global Healthcare Conference on June 4, 2025 [1] - The event will feature key executives including the CEO, CFO, and Chief Business Officer [1] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases [3] - The company is currently developing and commercializing products for pulmonary hypertension using its proprietary PRINT Technology [3] - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3] - The company is also working on L606, an investigational sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3]

Core Viewpoint - Liquidia Corporation is focused on the potential commercialization of YUTREPIA, an inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), with an FDA decision expected by May 24, 2025 [2][3][8]. Corporate Updates - The FDA accepted Liquidia's New Drug Application (NDA) resubmission for YUTREPIA, setting a PDUFA goal date of May 24, 2025, coinciding with the expiration of regulatory exclusivity for Tyvaso DPI [3][8]. - A U.S. District Court dismissed a cross-claim from United Therapeutics challenging the NDA amendment for YUTREPIA, allowing Liquidia to proceed without legal hindrance [4][8]. - Liquidia completed enrollment of Cohort A in the ASCENT study, with over 50 patients, showing promising results in dosing and tolerability [5][8]. Financial Position - Liquidia entered into a sixth amendment with HealthCare Royalty, allowing for up to an additional $100 million in financing to support the development of YUTREPIA and other clinical trials [6][8]. - As of March 31, 2025, cash and cash equivalents were $169.8 million, a decrease from $176.5 million at the end of 2024 [7][8]. - Revenue for Q1 2025 was $3.1 million, a slight increase from $3.0 million in Q1 2024, primarily from a promotion agreement with Sandoz [9][8]. Expenses and Losses - Research and development expenses decreased by 31% to $7.0 million in Q1 2025, down from $10.1 million in Q1 2024, due to a shift in focus towards commercialization [11][8]. - General and administrative expenses rose by 48% to $30.1 million in Q1 2025, attributed to increased personnel costs and legal fees [12][8]. - The net loss for Q1 2025 was $38.4 million, or $0.45 per share, compared to a net loss of $30.1 million, or $0.40 per share, in Q1 2024 [14][8].

Core Insights - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] Group 1: Company Overview - Liquidia's current focus includes the development and commercialization of products for pulmonary hypertension and other applications of its proprietary PRINT Technology [3] - The lead candidate, YUTREPIA™ (treprostinil) inhalation powder, is an investigational drug aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3] Group 2: Upcoming Events - The Chief Financial Officer and Chief Operating Officer, Michael Kaseta, along with Chief Medical Officer, Rajeev Saggar, will provide a business update at the BofA Securities 2025 Health Care Conference on May 13, 2025 [1] - The event will be accessible via a webcast on Liquidia's website, with an archived version available for at least 30 days post-event [2]

Core Points - Liquidia Corporation will report its first quarter 2025 financial results on May 8, 2025, and will host a webcast at 8:30 a.m. Eastern Time to discuss these results and provide a corporate update [1][2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's primary focus includes the development and commercialization of products for pulmonary hypertension, utilizing its proprietary PRINT Technology [3] - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3]